AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...
AbbVie said its Rinvoq showed superiority over the company’s previous bestselling drug Humira in a head-to-head trial. Results showed that 43% of patients compared to 22% of patients on Humira ...
() -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, meeting the main goal of a head-to-head trial. (Reporting by Puyaan Singh in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback